Lakefront Biotherapeutics (LKFT) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 113.4% versus a loss of 14.5%. Over five years, URGN leads with a +117.3% price change compared with -44.9% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($1.93 billion vs $1.81 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | URGN |
|---|---|---|
| Share price | $29.51 | $36.98 |
| Market cap | $1.93B | $1.81B |
| 1-day change | -1.63% | -9.14% |
| YTD return | -9.76% | +57.90% |
| 1-year return | -14.46% | +113.39% |
| 5-year return | -44.86% | +117.27% |
| P/E ratio (TTM) | 2.81 | — |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $10.52 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $36.24 | $50.81 |
| 52-week low | $25.68 | $15.86 |
| Distance from 52-week high | -18.57% | -27.22% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +2.27% | +62.25% |
| Average volume | 273.30K | 849.01K |
| Shares outstanding | 65.48M | 48.88M |
| Employees | 196 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed LKFT by 127.9 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
LKFT vs URGN FAQ
Which is bigger, Lakefront Biotherapeutics or UroGen Pharma?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.93B compared with $1.81B for UroGen Pharma (URGN).
Which stock has performed better over the past year, LKFT or URGN?
URGN returned +113.39% over the past 12 months, compared with -14.46% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.